Hi, welcome everyone to the first earnings call ever as BICO, we will present our second quarter for 2021. This is a historical call, since this is the first BICO call. The earnings call will be divided into two parts. First, we will have a section where Gusten will dive into the earnings, Erik will tell us what BICO and bioconvergence is all about. After that, we will host the Q&A session, where I will be back with further instructions if you wish to participate. You can already now use the Live Events Q&A to the right and pose the questions, those questions will be released during the Q&A session. By that, I will hand over to Erik. Thank you so much for that, Isabelle, and I hope everybody's doing well. I would like to thank you for calling in today and joining our earnings call presentation for the Q2 report that we just released this morning. Today is a great day, of course, not only from the perspective of releasing a quarter two report, but it's also, of course, a great day in terms of launching of our new brand and our new organizational architecture that we will go through in more detail throughout the presentation. We can go to the next slide, please. The agenda for today is we're going to start by covering essentially the financials for Q2 and the first half year of 2021. We will then proceed with discussing more about BICO as the company's now positioning ourselves as the leading bioconvergence company and how we anticipate to bring this bioconvergence revolution to reality. We will also discuss our acquisitions during Q2, so bringing on our both American and German colleagues. Of course, we will end the session with a Q&A session. With that, I'd like to, of course, thank you everyone again for joining. I really look forward to discussing these great topics with you, and let's get started. You can go to next slide, please. Something very well worth mentioning is, of course, the pride and the thankfulness that I have for all the amazing colleagues, investors, shareholders, and everybody that are on board on this journey. In just five years, we have managed to build a world-leading group that offers truly something unique other than life science companies and biotech companies in different industries. I'm very proud to state that over these last five short years, we've managed to go from essentially what started as just actually three individuals to now close to 1,000 employees around the world, products in more than 2,000 laboratories. Something that strikes me as perhaps even most impressive is the amount of publications that researchers and scientists have managed to publish in this short amount of time using our products and technologies. Of course, market cap and total addressable markets are in the right levels. To be fair about being what is most important is really thankfulness about these amazing colleagues, these 1,000 employees that are with us today and who will help us really bring this company to the next level. Next slide, please. With that being said, I'm so proud to present our new architecture and our new brand. Under this new brand, and I've noticed a little bit of communication out in the open, of course, I read all of these things, but sometimes I hinder myself from answering to all of them. I would like to say that BICO is a great name for the journey we have ahead of us. CELLINK got us here, BICO is going to get us there. The reason I'm saying this is because, first of all, CELLINK, the company that we built over the last couple of years, will continue to be the leader in the bioprinting industry. Bioprinting is one of these great legs that we have that the company is fundamentally standing upon. We have the legs of bioprinting, we're standing on multi-omics applications, we're standing on cell line development, and we're standing on diagnostics. While CELLINK will continue to live on as the great leading company it is, BICO will take on the position as the bioconvergence leader and really bring in this industry to a whole new level. It's beautiful to see these two, we call them the double helix, and these two arrows that you see above the logo, they really represent what we are all about, and that is speed to market, getting our technologies and products and acquisitions to market and serve our customers' needs. These symbols will remind us on a daily basis that the products and technologies that we offer, they impact human lives around the world. That's something that we take with us with great pride and makes us very happy to continue this journey ahead. Let's go to next slide. In terms of our financials for Q2 on the first half year, I am, of course, very proud and thankful to say that we have achieved a strong organic growth. We've achieved a strong total growth looking from year-over-year. We've achieved a positive EBITDA, and we're standing very well in line with the targets that we have communicated over the last couple of years. With that being said, I want to introduce my very good colleague, Gusten, and I want him to take over and discuss the numbers in more detail. Thank you for that, Erik. It's a great pleasure today to present this quarterly report, of course, with some very exciting numbers. This is the results of a lot of very hard work across the whole organization during the last couple of months that are now presented to you here. We can go to the next slide, please. In terms of net sales during Q2, we reached SEK 293 million, which was up from SEK 40 million last year, corresponding to about 628% growth, which was last year about 36%. Maybe even more exciting is that the businesses that we've had in the portfolio for over a year, in the group for over a year, has been growing very rapidly. The organic growth was 95%, also the acquired entities themselves have been growing very rapidly since the acquisitions. This is very pleasing to see. If we look a little bit comparing only also from Q1, we see almost 30% quarter-on-quarter organic growth and over 120% quarter-on-quarter growth in total. It's very rapid growth right now, and the reasons for this are a couple, but we see that the reopening in the U.S. has contributed a lot to the increased growth rate, as well as seeing that because our customers are using the instruments more, coming back to the laboratories, which is driving demand. I'll come back a little bit to this later on in the presentation. It's also exciting to see that we have a positive EBITDA in the second quarter. We reached about SEK 10 million during Q2, which is up from -SEK 16 million last year and a negative EBITDA in Q1 as well. This is very nice to see that we're on the right side there again, about 3.6% margin. Down to the profit loss, or the bottom line, we have a negative bottom line, which is in line with our plan here. The main differences between EBITDA and the profit and loss for us are the amortization of intangible assets in the balance sheets, and these are, of course, a result of the identified assets in the M&A that we do. When we acquire an entity, we have to identify and allocate the appropriate assets to, for instance, intangible assets and write this off over a certain period of time, as well as the in-house developed assets and technologies that we write off, and this is about SEK 40 million in the quarter. On top of that, we also have about SEK 18 million in interest costs related to our recently issued convertible note. Just a short note on that is that we have a coupon which is about 2.875%, but in the accounting, we do account for the effective interest rate, which is basically you account for how much the option of the convertible is worth, and this translates to about an effective interest rate about 5.8%, which is really the interest cost here. That's the difference between EBITDA and net profit. If we go into our gross margin, we see it's quite aligned with the gross margin from last year, 69% versus 70% last year. What's even more pleasing to see is that the comparable businesses, basically the businesses we had in Q2 last year, has actually increased then from 70.2% up to 75.9% gross margin. We've seen a very positive gross margin development. The reason why it's lower than in Q1, where we had very strong gross margin, is more about the total product mix with the new companies entering the group. For instance, we have some businesses that have lower gross margins but have less costs further down the P&L. For instance, we have Nanoscribe and also maybe more significantly, we have Ginolis, who has a lot lower gross margin than a lot of the business we've had before, and therefore the comparative number in total here is lower. I'll get back a little bit more to that later as well. Also pleasing to see, as I mentioned earlier here, is that we've had an increase of sales on consumables and reagents. It's now SEK 61 million in the quarter. Last year was about SEK 8 million or SEK 9 million. This is an increase with over 600% year-over-year. The share of our total product sales is about 23.4%. What we're seeing here is a very large increase in absolute numbers, also an increase in relative numbers. I'll get back to this and describe this more in detail. If we look a little bit on the first half year before we move on here, we see that net sales for the first half year surpassed SEK 420 million. Just a small note also, over the last 12 months rolling, we just surpassed SEK 700 million in net sales as well. This is very strong growth there, about 440% for the first half year, where almost 80% of that was organic. Very strong organic growth for the first half year here, of course stronger than last year. What we can comment here is that we see and we've continued to tell you in the reports and during this call, so the previous year here or the past year, that the pandemic has had a negative effect on the majority of our business, where we now see more and more laboratories that did open up during Q2. That has helped us increase our sales and activities that we can do. This is, of course, a trend that we all hope will continue so we can get back to normal. We have a few businesses that have some COVID business. These are mainly related to production equipment for instance, antigen production and so on. We have Ginolis as well as Scienion working with this. It's a smaller part of our total revenue. Over time, we see this to be somewhat decreasing as a portion of the total. It's not as significant on the group basis right now. On a whole group level, EBITDA in the first half-year is still negative. It's about SEK -24 million, which is very similar to the previous year in absolute numbers. Our gross margin for the first half-year was 71.6%. Also, if you're just looking at the comparative or the organic businesses, so to say, we had 78.5%. Very strong gross margins here. Next slide, please. If we're looking at the net sales development, it's been very strong over the past year here. It's been fueled by M&A as well as strong organic growth, where, of course, here in the past 2 quarters especially, we've had a significant boost where we include more businesses into our reporting. To point out a little bit here, in Q2 now from this year, we have Ginolis and MatTek who's included for the full quarter. We have Nanoscribe and Visikol, which are included 1 month in this quarter. We have Discover Echo, which isn't included at all in the P&L, but they're fully incorporated into the balance sheet. What this gives us is, in fact, if you go down and compare, is that we see that the balances all look inflated in relation to our revenue or our size due to the fact that they're all included in the balances, but not all included in the revenue for the quarter. If you go into the details of the report, you can see how much all these acquisitions would have contributed with if they would've been part of the group for the first 6 months of this year as well. In this chart you see here, we have a metric that we started tracking here, which is especially interesting when we're doing some M&A as well to see that we're doing value-accretive transactions. We want to make sure that you see we can follow on track to increase the revenue per share outstanding as well as in the future here, of course, our EBITDA per share. In the end, it's of course the free cash flow or the net earnings per share that will be interesting. This is a start, so we can go to the next slide, please. If looking at the gross margin and the gross profit here, of course, in absolute numbers, it's increasing very rapidly due to the size of the business increasing so heavily. Also in terms of the margin levels, as I described earlier, we've had a very positive development on the business that we've had for a while. The reason for this is that we see more high-ticket items, meaning that, for instance, in the bioprinting business, we're selling more and more BIO X6, which is the more advanced system of the BIO X or the new bigger brother, so to say, which list price or sales price is about twice from the BIO X. This, of course, fuels gross margin and profit. We see this across the business where we have, for instance, in Cytena, going into the UP.SIGHT generation from the F.SIGHT and C.SIGHT products that was sold a lot before that, but still, of course, part of the portfolio. Of course, the high proportion of sales that stem from consumables and reagents, the better the gross profit will be since we have a slightly better margin on the consumable and reagents. However, the more important aspect we'd see increase there is connected to that they don't drive OPEX in the same way. We'll get back to this in the next slide. What is good to understand here in the gross profits before we get to the next slide here, and before what's good to see here or important to understand is also the product composition or the companies included here, as I mentioned. We have, for instance, Ginolis, which has a lot lower gross profits and margin structure in the 40s. Meanwhile, we have some businesses in the 70s right up to the 80s. As we grow, the more interesting part is, of course, how to see how this develops as we have them in the group. Meanwhile, the different transactions we bring in and will bring into the future might have a negative, positive effect on the absolute number here. It's just something to keep track of and make a difference between. We can go to the next slide now. If looking at the net sales from consumables and reagents, this increased with over 600% year-on-year. If we're looking at out of the total sales in Q2 isolated, it was 22% and close to 24% if we're looking on out of the product sales. The consequences or the reasons for the rapid increase here is mainly that the demand for consumables are increasing as the installed base are increasing. We also see that the customers coming back to laboratories are buying more of these consumables and reagents. We see that we, as an organization, are also getting better with coupling instruments with reagents and consumables driving this development. Of course, in absolute numbers, why we see such an increases that we added MatTek to our business, which have a high proportion of sales coming from consumables and reagents. This boosts the absolute number. Meanwhile, in relative numbers to our total sales, we don't see an M&A-driven boost here since we have company such as Ginolis and Nanoscribe that have very low proportion of sales through consumables and reagents. If we're looking at the old business that we had in Q2 last year, they have above the average of the total group sales of reagents and consumables. We can go to the next slide. Very exciting to see the strong growth in the North American market in Q2, where we saw the organic growth. Remember, this is not related to the whole business, but the organic business. We saw 164% organic growth in the North American market, which is extraordinary, of course. This is related to an excellent work by the sales team here in the U.S., as well as the reopening of the markets, more activities, and being able to go out to laboratories as well. We see somewhat of a lagging market in Europe with slower reopenings and less activities where we can get out to customers. We're also working on things on our side to be able to accelerate this into future quarters. We see strong growth, of course, rest of the world from very low numbers, but growing very rapidly, partly due to a new initiative where we're opening an office in Saudi Arabia, which has been driving this. Of course, Asia has been growing very rapidly also during the second quarter. About half of the revenue from North America, and about 40% from Europe, and then about 15% from the rest of the world and Asia. With that, I would like to hand this back to Erik, which will take you through the rest of the presentation here. Thank you so much for that, Gusten, and great job with the numbers. With that being said, I want to go through a little bit more about the Bioconvergence Revolution, the new brand, the architecture around the organization, and how I perceive that we are best positioned to take on these healthcare challenges that we will be working with for the next coming decades. You can go to next slide, please. As a bioconvergence company, of course, our mission really is to solve some of the world's biggest health challenges. We will do this through the convergence of scientific disciplines such as biology, conventional engineering, including mechanical engineering, biomechanical engineering, electronic engineering, computer science, robotics, and a wide range of automation. I believe strongly that if you combine these disciplines with the discipline of biology, all of the sudden you can start answering much more complex questions. The reason I say that is because from what I've seen in the field and from what I see that our customers are doing, the field is really moving forward very rapidly in terms of how can we improve data collection from disease models or from patients' disease. How can our treatments become more personalized? How can we combine, for instance, mechanical products or mechanical solutions together with essentially biological solutions for new implants or hybrid models? Most importantly really is to answer these questions, we have to find some kind of combination and a middle ground in between these different disciplines. I'm really excited about this strategy because I see that as a company, we're starting to develop a more of a blue ocean strategy and providing workflows to our customers around the world that can truly work in the field of bioconvergence and get help from it to start treating patients much sooner. We can go to next slide. Let's talk a little bit about the challenges that we're actually facing here. The challenges, as you know, and as you've followed the company on your journey or if this is your first time hearing us talk about it, we're really working with three major challenges. The first one is preventing future pandemics. I mean, this is a slam dunk application today since this is one of the major challenges that the world is facing. Really the answer to being able to prevent future pandemics is, of course, increased testing. It's about understanding disease faster and being able to model disease, and then, of course, being able to either develop different diagnostics for it or being able to develop different treatments. The second challenge that we're facing is that 9 out of 10 drugs, they fail in the clinical stages of development. It takes about 10- 12 years for pharmaceutical companies to develop new drugs, and the cost of it is more than $2 billion. The reality again is that 9 out of 10 of those drugs that go through the development process, they fail right in the clinical stages. Lastly, of course, something that is I think close to everybody's heart, and something that we have been so proud of working with ever since the beginning of this entire journey is really that a life is lost every hour of the day due to the lack of organ transplants. This can be very, very sophisticated and challenging transplants such as hearts, but it can also be more simplistic organs, such as the largest organ on the human body, which is your skin. A lot of damages happen when major fires or in military exercises or wherever it may be, and this causes obviously long-term or lifelong damages or troubles for patients. These are essentially three major challenges that we're focusing. Of course, in between, there are a lot of additional challenges that patients face that we need to be ready to attack. If you go to the next slide, I can talk a little about how we will be working with a wide range of technology platforms to really answer these. If we're looking at bioconvergence and what this is really all about it's about combination of technologies such as digital platforms. It's about artificial intelligence. It's about large computing. It's about taking mechanical engineering and automation and applying it towards the biology field. What do you get from that? Well, you get disciplines such as bioprinting. Bioprinting is a perfect example of the combination of mechanical or added manufacturing, combined together with material science and material engineering. If you do that, all of a sudden you can start creating things that you would not be able to do before, which is potential implants or organs or tissues that can be used for transplantation. The same concept applies to other industries that we're currently penetrating into, which is, first of all, cell line development. We can help by speed up the rate of clone selection and biological drug manufacturing. We can help with single-cell sorting or sample preparation for the genomics or proteomics industry and these applications. We can also help diagnostics companies manufacture better diagnostics kits that are more relevant for testing, that can test more different diseases, because we're using a wide range of technologies that other companies haven't done in the past. Let's look at how the company's structured, really, in this new constellation. We can go to next slide. It's not really much different from it was before, right? We still have three business areas. One of the business areas is now named Bioautomation to fit more of the biological umbrella that we're approaching. We're essentially working in three main business areas, bioprinting, biosciences, and bioautomation. If we look at, first of all, bioprinting. Bioprinting is all about tissue and disease model creation. It's all about how can we create the actual cellular or tissue model that can then later be studied. This tissue model can, first of all, of course, be used for pharma or drug discovery or cosmetic product development. For instance, printing skin or producing skin in a laboratory, that can be used to develop cosmetic product instead of using animals. The second business area, bioscience, is all about disease and tissue analysis. In this area, we work heavily with single cell multi-omics. We work with cell line development as one of the bioapplications of these products. We're also working heavily, for instance, with microscopy, which is a very conventional method of analysis, but we're applying our Bioconvergence filter to that market and using a lot of new computational models, software improvements to ensure that the customer is getting the ideal solution for their applications. The last business area is our Bioautomation, which is all about tissue and disease mastering. To master disease, you have to be able to diagnose it much earlier. At much earlier stages, you can understand what you're dealing with, and in turn, that will help you develop better treatments faster, and hopefully, more personalized. These are, of course, in generally very large markets. Looking at a total application area, we're looking at about SEK 150 billion approachable market. Of course, today, the market share at which we're penetrating is a portion of that. We anticipate that to be the overall market opportunity for the company moving forward for the next coming years. We can go to next slide, please. If we're looking at the architecture again, BICO Group is the mother company and is the front-facing entity that will be facing shareholders, investors, and essentially also even consolidating to some approach on conferences and perhaps even to customers for certain applications. What we want to do is that we want to put the control, and we want to put as much effort into the daughter company as possible, so that they can lead by example, and they can lead with the great technology that they have developed. For us, we kind of have a saying that it doesn't make sense to acquire great products, technologies, and most importantly, teams, if you're going to lose that. For us, it's all about cultivating the teams that are acquired. It's about being able to do a very strategic integration of acquired entities and to maintain the knowledge and expertise with the companies. For that reason, we have chosen a relatively decentralized approach that focuses heavily on highlighting the great things that these daughter companies are doing, and motivate them, inspire them, and ensure that their R&D pipelines are in line with our bioconvergence strategy, and that together, we will create the future of health. You can go to next slide, please. As being a bioconvergence powerhouse, the development agenda in R&D is essentially on BICO level, where we can see a more holistic perspective on where the company's going. For instance, as I mentioned, one of the very hot areas that we're working in is really the area of medical implants. If we're looking at medical implants today, many implants are made out of titanium or plastic or synthetic materials. If you want to start going for more biological implants, using different collagen materials or different biological materials, you're going to have to improve the way that we manufacture these implants. For that reason, we managed to develop our first actually synergy product between CELLINK, bioprinting, and Cytena, which is the BIO MDX product. This product is really taking the leadership position in that industry, and it's going to be the pioneering product that will pave the way forward for new implants and for potential hybrid implants also going forward. That's really exciting because all of a sudden, BICO has set the agenda for that industry and for that application, and the daughter companies, they have provided their excellent products and technology and expertise. Together, unitedly, we've managed to bring a new product and new technology to the market. This is really the beauty of the bioconvergence, and this is the way that we will be working with the strong development agenda, and a combined R&D entity. Of course, we will be able to offer market-leading products and customized workflows. We will be able to find synergies within the group, both from a sales perspective, but hopefully also from operational logistics perspective, where we can work with similar ERP systems or CRM systems, get access to each other's customers, and ensure that we maximize the collaborative nature in which these companies in our group are working. We will, of course, also continue to inspire and highly motivate all of our colleagues to continue this innovative and entrepreneurial culture that we have built from the beginning, because that's, we believe is going to be the fastest approach to new treatments for patients. As Gusten had mentioned already, of course, our M&A agenda will continue forward. This is an important aspect of the BICO strategy. We will continue to both develop technologies that are based on customer feedback and customer needs, but we will also acquire companies, and we will do so as quickly as we have to. We understand that this industry is very fast moving, and that means that we have to stay on top of the game at all times. Of which, actually, again, I have to reference you to our new logo, which are the two, the double helix, which actually stands for then future forward fast. Next slide, please. Something very important that I mentioned is, of course, always having the customer's best at heart, and that's our continued customer obsession agenda. We believe that the answer to our strategy moving forward will be coming from our customers. It will not be coming from a headquarter or from an office where we sit and come up with cool ideas. We have to continue to be very involved in our communities and listen to our users to make sure that they help us draft the future of what bioconvergence entails. Next slide, please. Let me talk a little bit about the acquisitions during Q2. We welcomed 3 very exciting companies, very exciting, yet different. We'll talk a bit about what these companies entail and what they have as a strategy moving forward. I will be covering a little bit more on the technical and synergy side of things, and then I'll let Gusten go over a little bit more about the transactional details and how we see that, potentially, we'll look at the process moving forward. We can go to next slide, please. Looking at these acquired companies, the first one, Nanoscribe, was acquired into the business area bioprinting. The focus of Nanoscribe, it's a beautiful company with great entrepreneurs that have really built a leading position in the field of two-photon printing. Two-photon printing is the ability to, and I'll try to be as elementary as I possibly can, it's the ability to print very tiny things that can be used for a wide range of applications. Of course, in our case, it's all about miniaturizing things, right? 10 years ago, it was all about making a reaction in a Petri dish. Well, now, researchers and scientists want to make reactions in tiny wells because they want to study single cells. Your substrates need to be smaller, your reactions need to be smaller because that will drive down the cost and the price, et cetera. I believe that with Nanoscribe, we'll be able to start miniaturizing a lot of things. We'll be able to look at ways that we can combine their technology with some of our cell line development, also some of our multi-omics applications. Very interesting company, very excited for their growth, and we look forward, of course, to continue to grow that. Another great company that was added was obviously Visikol. Visikol, under the leadership of two gentlemen out in New Jersey. Visikol is very interesting because it is our first ability to enter into more of a CRO market. It enables us, essentially, if I try to explain very simply, if we can't come to our customers because our customers' labs are closed, our customers need to be able to come to us. That essentially provides us with an ability to offer CRO services and ability to do studies for our users, specifically in the pharma industry, in our laboratories, and then provide them with the results. No matter where they are and what our customers are doing, they should always be able to work with us. For that reason, I believe that this is a very strategic expansion. Lastly is Discover Echo, a beautiful company focused on revolutionary microscopy technologies. They've really revolutionized that industry. They're taking a very aggressive approach on disrupting and making a lot of digital change to the industry. This is what we're all about. This is how we started our bioprinting technology business. This is how we will continue to grow rapidly in the future. With that being said, Gusten, I'll let you cover a few words on the process moving forward. Yeah, no, absolutely. We'll just go briefly through these transactions. We raised some capital earlier this year, about SEK 3 billion, and we put a fair bit of that into work, where you see the transaction multiples as well as transaction value on this slide here. For these three transactions, in total is about SEK 1.7 billion. All three contribute fully to our sales from Q3 this year. These transactions, two of them have a significant earn-outs component to the transaction, which we haven't used that much before. How you'll be able to follow this and see this is in our balance sheet, we have a estimation on how much of this debt will be paid out, and that will be assessed on a continuous basis, so you can follow that. Hopefully, in best case scenario, will pay out all of this. Then these companies perform very well and aligned with what they've hoped for. Worth mentioning is that we continued with the approach that we've had since the beginning with making transactions both with a cash purchase price as well as a share allocation. You see it differs a lot between the different transactions on how much is paid in cash versus shares and so on. This is always a little bit misleading because it depends on how you're looking at it. For instance, ECCO had a few hundred shareholders, but only a few of them received shares. For them, they received a lot more shares. These are the entrepreneurs and the employees in the companies who's going to stay there and build this company together with us. We're very excited about that transaction and the structure of how this is done. Looking forward, we've done five transactions in the first half year now. We have this active agenda, as Erik described. We'll continue working in the same way as we've initiated this year, and we'll see what that will render in terms of transactions and so on. What we see is we have the ability to look at more cases, we can be more critical and really spend the resources, and we have more people to be able to assess what's right to move forward. We see that this is very promising for what we'll be able to add in the future. With that, I think we can go to the next slide. Yeah. If we look a little bit more on what I was mentioning about Visikol and the acquisition to be able to offer more services and actually enter into a new segment for us, it's a beautiful example of how the bioconvergence technology is really working. It's a combination of AI imaging analysis. It's a combination of very advanced imaging tools. It's a combination of cell culturing, that's where you have the biology aspect. With this combination of these three pillars, all of a sudden you can start giving these pharmaceutical customers and users more insight, better data, which will hopefully lead to better therapeutics for patients around the world. We're very excited to have Visikol on board. We've already started seeing great synergies between companies in the business area. We will continue to, of course, push for strong collaborations with our customers and always listen to their needs. With that being said, I would like to thank you so much for your time and for your attention. I would also like to, again, extend my greatest gratitude and thankfulness to the entire team for the amazing work that everybody has done to achieve this fantastic growth. I am so proud of everybody, and I look forward to answering some of your questions. Okay. Thank you for great presentation, Erik and Gusten. Let's move on to the Q&A session. If you are joined online, you can use the live event Q&A to the right and post questions. If you're calling in, you can ask questions directly to the speaker. We have a few participants who have addressed they would like to ask questions. We will begin with one question from online, and I will read it out loud. Let's see. With expanded strategic agenda from bioprinting inks to Bioconvergence, how should an investor understand the relevance of the current financial targets? Can you elaborate a little bit about this, please? Yeah, I can address this from the financial targets perspective here. The way to look at this is that we've set an agenda for how our priorities are from 2019- 2022 in terms of revenue and profitability. What we said is that we are focusing on growth, and we want to grow as fast as possible without running into the red on EBITDA, meaning we want to maintain a positive EBITDA and a minimum of 35% organic growth during this period. We haven't made any adjustment to this target, and we're likely to look into this target during the next year or so in order to update for our expectations for the next few years to come. In general, we've acquired businesses that are also acting in fast-growing niches. If they're not, at least they are disruptors in the market where they are, where they'll be able to grow faster than the market. Therefore, we see that most of the businesses in the group today have an ambition to grow in accordance or aligned with our financial targets. We don't see any need of changing or addressing the financial targets right now. Thank you, Gusten. We have some questions online. The first one is from Ulrik Trattner from Carnegie. Please go ahead, Ulrik, and you do so by unmute yourself by pressing star and six. Great. Thank you very much, Isabelle. Good day both to Erik and Gusten. I have a few questions, if I may. First of all, congratulations on a great quarter. If we can start off with the organic development split. Just trying here to decide for majority of sales, I would assume, which is organic, is from your old laboratory solutions. If you can please help us provide with a bit more information on which type of systems are driving this development or any specific applications as well as how does the revenue split between consumables and system looks from an organic perspective? That would be my first question, please. Okay. I think I can address that. If we're looking at organic growth, what's counted in there is the businesses from CELLINK bioprinting from Cytena and from Dispendix, which are the th companies that are fully organic in Q2. No other businesses contribute to the organic sales. What this means in product lines is basically bioprinters, liquid handling in terms of nanodispensing or nanoliter dispensing, as well as bioprocessing solutions for single-cell dispensing, et cetera. If we're looking more on what kind of instruments have been driving the organic growth during the quarter, we see a strong pickup, both from pharma as well as from academia, especially in the U.S. We see that more customers choose the more high-end equipment we have in our portfolio going up to, for instance, BIO X6 instead of the BIO X. In this quarter, in terms of organic growth, the bioprinting is a very heavy contributor to the growth here. In addition to that, we see that Dispendix with the liquid handling aspects here or the nanoliter dispensing, has also contributed a lot to the organic growth. In absolute numbers it is less, but they are growing from smaller numbers from last year. That is the main drivers during Q2 of the organic growth. If we are looking at the consumables and reagents in relation to product sales for these three companies combined, we do not disclose it exactly, but it is just slightly above the average of the whole company at this stage. The added-on acquisitions we have to the group today have had a slight negative impact on the proportional sales stemming from consumables and reagents. Of course, a positive impact on the absolute number of sales stemming from this segment. Great. Thank you, Gusten. If we were to move on to, as you mentioned, there is an opening up in the U.S., and I know that we talked, or you talked about last year, that around 50% of the commercial labs and 70% of the academic labs were closed down during the sort of peak of the pandemic. How is this ratio now? Would you call it out to be close to fully open as well? 164% organic growth in the U.S. is obviously impressive, but now you have built your own organization around Europe. Would you call it out to be successful as of yet, or is it too early to call out how much of the pandemic has slowed down your transitioning from distributor to being your own sales organization? What should we expect in the next few quarters, from both the European and Asian markets, beyond, and obviously the sort of the good development in the U.S.? That's a great question, Ulrik. I can hop on that one first, and Gust you can add more to it if you want. I want to start by saying, I think that the only reason that we're seeing growth in Europe right now is because we have a direct sales force. That's a pretty stark statement, but I want to back that up a little bit. The distributors that we've seen in Europe, many of these companies basically threw in the towel in the beginning of the pandemic, and many of these companies have focused heavily to transition to sales of products that were immediately needed for combating the pandemic. For instance, if you're a distributor and you're selling products that can be used for production of cell media or that can be used for the production of vaccines, and then you have also an arm that are used for laboratory equipment that can be used for genomics or can be used for bioprinting, you're going to focus all your attention on the products that can be used for production of vaccines. With that being said, that's nothing that I could control or nothing that our sales managers or sales reps could control in that case. We would not be able to force distributors and companies to switch their focus on different products. It's their business. They have to protect their business exactly the same way that we have to protect our business. For that reason, I believe that we did the right decision by establishing our own sales force in Europe. For that reason, we have been able to actually show growth during this very difficult time period. I want to hop over a little bit to the U.S., where we've seen the market open up quite nicely over Q2. The fact is, you've seen laboratories have started back up. You've seen customers return. We've seen research ongoing, and that's very positive, and that's been driving the majority of our growth, I think. That will, of course, return to Europe, I believe, in a certain amount of time. When, I don't know. What I'm seeing now is that Europe is still being very cautious in terms of returning to business as usual. You're not seeing sort of difference in willingness in adopt this new type of technologies or incorporating cell line development? No Further? It's not a challenge. Everybody is super interested in the products. The products are hot. The applications are very hot. It's just that, when our customers in the U.S. say that it's hot, they're ready to make a commitment because they are in the laboratory, and they need the products. When the customers in Europe say that it's hot, then they're evaluating, and they're saying, "Once I'm back in the laboratory, I'd be willing to place an order. I'd be willing to continue that conversation." That's the challenge. It's a time question, and that's of course painful to watch, but that's also why we're trying to introduce more ways of working with customers in Europe, perhaps through different CRO models, delivering the tissues instead of perhaps the equipment to print the tissue, and being innovative about our business model. I think that's going to be helpful. Great. Two more questions on my end, if I may, and then moving on perhaps to the industrial solutions, and obviously a very strong quarter. I think one needs to address how much is COVID-related out of these deliveries. As well as since it is quite lumpy in terms of revenues from the segments, heavily tilted towards the end of the year. Can you help us provide with some more granularity on the order backlog, how it looks, if you're comfortable in growth going into 2022 as well, sort of beyond the pandemic? You're muted, Gusten. Sure. If we look at some of our business historically, how they perform, we see that especially the bioautomation with Cytena and Ginolis have had a strong end of the year with deliveries and a lot of budgets that needs to be closed out and so on. If we're looking historically, that's what we've seen, that Q4 has been stronger than Q3. We see in terms of the COVID business that, for us, the best is if the impact of COVID disappears, that would benefit our business the greatest. We do, on the other hand, of course, have some business, which are sold to companies, diagnostic companies and so on, working on applications here. However, if we see a decline from nations in terms of wanting to have pandemic preparedness or pandemic preventions in the next two years when they've been able to establish these centers, we see that the demand from our ordinary customers will most likely replace that quite rapidly as we now have to prioritize the more urgent orders in many cases. This is also just a small part of what these two businesses are doing. It's not significant in that way. Great. Thank you, Gusten. Last question on my end, and sorry for asking so many. Just on your sort of M&A strategy in your last acquisitions and the risk that Nanoscribe, obviously it looks like quite similar technology to Holograph-X, that it cannibalizes on that development. As well as following that on the Visikol, it operates quite a different CRO business model. Did you believe that that would be an opportunity for the entire bioprinting segment to operate through a CRO model partly, in order for that to increase adoption among your end customers? I think if I start with the first one, we don't see, we don't perceive any cannibalization effects from the Nanoscribe business and Nanoscribe Technologies. It's the opposite. We see a possibility to open up different price points and expand that product portfolio to ensure that we can penetrate from different sides of that market, both from a cost-effective standpoint, but also more from a technological and advancement standpoint. I think that it's been a very positive positioning through that acquisition. In terms of Visikol, I would love to see more bioprinting offerings through contract research. Yeah. For research contracts, because I believe that will speed up the rate of adoption. It will also enable us to get into even more cost-effective laboratories and catch user at a much earlier stage. If somebody's not interested in making an investment to buy a printer or an equipment today, then perhaps we can start off with a smaller exploratory study where we can prove, show the result that the customer wants to see. From that, we can take that into enabling these users to either continue with contract research or they can get their own products and equipment in their laboratories to continue on their own side. I definitely see the CRO approach as a major enabler and a market opener for us. Great. Thank you very much, everyone, for answering my questions. I'll get back into queue. Thank you, Ulrik. We have also Johan Lindén from ABG on the line. Please unmute yourself by pressing star and six. All right. Hopefully everyone can hear me. Thank you for taking my questions. First one, can you talk a bit on the magnitude of the impact from the late orders coming in in Q1 into this quarter, and perhaps also which segment the revenues came in, just to get a bit better understanding from that one? Yeah, I think if we're looking at this, there's a couple of different ways we can address here. In the bioautomation segment, we have a continuous big backlog. Delivery times here could be up to one year for some of the equipment due to the backlog we have there. The more rollover we saw is more of the laboratory solutions kind of equipment, where we see shorter delivery times. How big the impact is here, we haven't quantified that exactly, and I don't have the exact number. It's not substantial. We're talking in a handful of million SEK in this quarter that we'd had a positive effect from that. Yes, this is something we'll see from quarter to quarter, and I think we had slightly more rollover from Q1 to Q2. All right. Thank you very much. You mentioned in the report also that some investments are being made, and I noticed that you mentioned investments in the area of single-cell proteomics. Are you seeing an increased interest in that area from commercial labs? Compared to genomics, it's quite early days in that area. Is that more preparatory to be ready for the future, so to speak? Can you talk a bit about that opportunity? Would be interesting. Absolutely. Specifically, actually, even on single-cell proteomics, it's, as you're saying, a very, very early application and a very early industry that's coming about. I love this because I see certain resemblances to the bioprinting industry where we could be very early with a disruptive product at the right price point and offer the ideal solution to the customer while continuously listening to their feedback and reiterating and coming back with new versions of products that will fit their needs as their needs expand over the coming years. I believe that our investments now in the field of proteomics are very strategic. We're betting quite big on the proteomics market will continue to grow very rapidly, we want to become one of those players that enable a wide range of sample prep possibilities for proteomics analysis. I think by investing heavily now and being early, having the right product mix and having the right product portfolio for it, we can take a leadership position in the next coming years. Right. Great. A final one from my side. Biosensors seems to be a very interesting area for potential M&A going forward. Given that it is such a broad segment, where are you focusing in that space, and what potential do you see in that segment would be interesting to hear a bit about. Yeah, that's a good one. I love where biosensors are going. I'm spending a lot of my nights reading on these types of applications and where that industry is headed. It's fascinating to see how much data and information you can gather from a drop of blood or a drop of sweat. The fact is, I categorize these things, it might be wrong, so don't quote me on it, but I categorize them essentially into two things, right? One is for disease modeling or disease analysis. Quite complex, right? You definitely need more than a drop of blood in that. You need quite a lot of blood, and that would be quite challenging analysis, and you want to do that based on regulatory environments and approvals. You have the more simplistic approach, which is essentially looking at kind of wearables and health detection and early signs of certain disease or early signs of things to keep in mind. I like this early sign market because it's kind of like the Apple Watch. It's kind of like these wearable rings and things like that because these are applications that will definitely determine and become a more personalized approach for users around the world. People will become a lot more interested in their health. People will become a lot more interested in specifically their treatments, their disease, as it's very different from others' disease. Our bodies are completely individual and separate from each other. That's how we need to see things in the field of medicine. I believe that really the biosensor and the wearables industry is going to drive a major revolution in terms of how diagnostics, treatment development, and even the entire drug discovery market is going to move. All right, great. It definitely sounds like something that could be of interest to expand within for you guys going forward, then. Yes. Great. Thanks. Thanks again for taking my questions. Have a good day ahead. Thank you again for your questions. Quite many questions today. I think next time we have to make room for more time in the Q&A. Actually later today, you will have a new chance because Gusten and Erik will join for Twitter Live on the BICO Group's Twitter account at 1:00 P.M. Eastern time and 7:00 P.M. Central European time. Stay tuned for that. If we move on to the next slide, please. Time travels fast when having fun, put a mark in your calendar for November 10th. This is the day we will release our next report for the third quarter for 2021. We can move to the last, final slide for today. This is what it's all about. Thank you everyone for listening in to BICO's first earnings call, and thank you for all the great questions being asked. Have a great Wednesday, everyone. Thank you and goodbye.